DZ Bank’s Apellis Pharmaceuticals APLS Stock Holding History

DZ Bank’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,208	Closed	-$93K	–	861
2018 Q1	$93K	Buy	+4,208	New	+$82.7K	﹤0.01%	1013

Other funds holding APLS

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DZ Bank's APLS Position: Q2 2018 in Review

DZ Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2018, closing a stake of 4,208 shares — an estimated $93K sold.

DZ Bank first reported a position in APLS in Q1 2018 and held it in 1 quarter. The position peaked at $93K in Q1 2018. 73 funds tracked by Wall St. Rank hold APLS as of Q2 2018.

DZ Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 4,208 Apellis Pharmaceuticals shares in Q2 2018, an estimated $93K.
DZ Bank first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 1 quarter.
DZ Bank's Apellis Pharmaceuticals position peaked at $93K in Q1 2018.
73 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.